Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.31 [0.01, 7.53]
1 study · 99 participants
Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.49 [0.09, 2.5]
2 studies · 125 participants
Low